KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs May 10, 2024 Poll Finding KFF’s latest Health Tracking Poll examines the public’s views and use of an an increasingly popular class of prescription drugs used for weight loss and to treat diabetes or prevent heart attacks or strokes. The poll finds 12% of adults report having taken one of these GLP-1 drugs, which include Ozempic, Webovy and Mounjaro. This includes 6% who say they are currently taking one of the drugs.
Poll: 1 in 8 Adults Say They’ve Taken a GLP-1 Drug, Including 4 in 10 of Those with Diabetes and 1 in 4 of Those with Heart Disease May 10, 2024 News Release About one in eight adults (12%) say they have taken one of an increasingly popular class of prescription drugs known as GLP-1s that are used for weight loss and to treat diabetes and reduce the risk of heart disease and stroke, a new KFF Health Tracking Poll finds. This includes…
An Estimated 1 in 4 Medicare Beneficiaries With Obesity or Overweight Could Be Eligible for Medicare Coverage of Wegovy, an Anti-Obesity Drug, to Reduce Heart Risk April 24, 2024 News Release In a new analysis, KFF finds that 3.6 million people with Medicare could be eligible for coverage of Wegovy (semaglutide) now that the Food and Drug Administration has approved the use of the anti-obesity drug to reduce the risk of heart attacks and stroke in certain patients. This change potentially…
A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity April 24, 2024 Issue Brief The FDA recently approved a new use for Wegovy, the blockbuster anti-obesity drug, to reduce the risk of heart attacks and stroke in people with cardiovascular disease who are overweight or obese – a decision that opens the door to Medicare coverage of Wegovy, which is prohibited by law from covering drugs used for obesity. This brief analyses how many Medicare beneficiaries could be eligible for the new use of Wegovy and the potential impact on Medicare spending.
Medicaid Utilization and Spending on New Drugs Used for Weight Loss September 8, 2023 Blog This brief discusses Medicaid coverage of weight-loss drugs, recent trends in Medicaid utilization and gross spending on new drugs used for weight loss, and the potential implications of those new drugs for Medicaid programs and enrollees.
Will Where You Live Determine Access and Coverage of Emerging Anti-Obesity Drugs? August 30, 2023 Blog The U.S. Midwest and South regions have higher average obesity rates among adults. What does this mean for access and coverage of prescription drugs for weight loss?
Obesity Rates Among Children: A Closer Look at Implications for Children Covered by Medicaid August 17, 2023 Issue Brief This brief examines the share of children with obesity, how obesity screening and treatment is covered under Medicaid for children, and what recent changes may mean for Medicaid programs and enrollees in the future.
Drugs Used for Weight Loss Could Cost Americans Much More Than People in Peer Countries August 17, 2023 News Release In addition to having the highest obesity rates, the U.S is currently facing significantly higher prices for several major drugs used for weight loss and other health needs, according to a new KFF analysis of the list prices for semaglutide and tirzepatide drugs. Ozempic, which has been approved in the…